

PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723** CLIENT PATIENT ID : UID:8178723
 ACCESSION NO : **0022VK005781** AGE : 33 Years SEX : Male ABHA NO :
 DRAWN : 26/11/2022 09:00:00 RECEIVED : 26/11/2022 09:02:13 REPORTED : 26/11/2022 12:46:30
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816
 CORP-OPD
 BILLNO-150122OPCR059785
 BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------

HAEMATOLOGY

CBC-5, EDTA WHOLE BLOOD

MORPHOLOGY

RBC PREDOMINANTLY NORMOCYTIC NORMOCHROMIC
 METHOD : MICROSCOPIC EXAMINATION
 WBC MILD LEUCOPENIA
 METHOD : MICROSCOPIC EXAMINATION
 PLATELETS ADEQUATE
 METHOD : MICROSCOPIC EXAMINATION

ERYTHROCYTE SEDIMENTATION RATE (ESR).WHOLE BLOOD

E.S.R 21 High 0 - 14 mm at 1 hr
 METHOD : WESTERGREN METHOD

CBC-5, EDTA WHOLE BLOOD

BLOOD COUNTS, EDTA WHOLE BLOOD

HEMOGLOBIN (HB)	13.2	13.0 - 17.0	g/dL
METHOD : SPECTROPHOTOMETRY			
RED BLOOD CELL (RBC) COUNT	4.08	Low 4.5 - 5.5	mil/ μ L
METHOD : ELECTRICAL IMPEDANCE			
WHITE BLOOD CELL (WBC) COUNT	3.73	Low 4.0 - 10.0	thou/ μ L
METHOD : DOUBLE HYDRODYNAMIC SEQUENTIAL SYSTEM(DHSS)CYTOMETRY			
PLATELET COUNT	216	150 - 410	thou/ μ L
METHOD : ELECTRICAL IMPEDANCE			
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	39.6	Low 40 - 50	%
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR VOLUME (MCV)	97.2	83 - 101	fL
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	32.4	High 27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC)	33.3	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			

SRL Ltd
 HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
 SECTOR 10,
 NAVI MUMBAI, 400703
 MAHARASHTRA, INDIA
 Tel : 022-39199222,022-49723322,
 022-49723322



PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723** CLIENT PATIENT ID : UID:8178723
 ACCESSION NO : **0022VK005781** AGE : 33 Years SEX : Male ABHA NO :
 DRAWN : 26/11/2022 09:00:00 RECEIVED : 26/11/2022 09:02:13 REPORTED : 26/11/2022 12:46:30
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

CLINICAL INFORMATION :
 UID:8178723 REQNO-1325816
 CORP-OPD
 BILLNO-150122OPCR059785
 BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval	
RED CELL DISTRIBUTION WIDTH (RDW)		16.7	High 11.6 - 14.0	%
METHOD : CALCULATED PARAMETER				
MENTZER INDEX		23.8		
MEAN PLATELET VOLUME (MPV)		12.5	High 6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER				
WBC DIFFERENTIAL COUNT				
NEUTROPHILS		61	40 - 80	%
METHOD : FLOW CYTOMETRY				
LYMPHOCYTES		25	20 - 40	%
METHOD : FLOW CYTOMETRY				
MONOCYTES		10	2 - 10	%
METHOD : FLOW CYTOMETRY				
EOSINOPHILS		4	1 - 6	%
METHOD : FLOW CYTOMETRY				
BASOPHILS		0	0 - 2	%
METHOD : FLOW CYTOMETRY				
ABSOLUTE NEUTROPHIL COUNT		2.28	2.0 - 7.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT		0.90	Low 1.0 - 3.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT		0.37	0.2 - 1.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT		0.15	0.02 - 0.50	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT		0	Low 0.02 - 0.10	thou/ μ L
METHOD : CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		3.2		
METHOD : CALCULATED PARAMETER				

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD-TEST DESCRIPTION :-
 Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

SRL Ltd
 HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
 SECTOR 10,
 NAVI MUMBAI, 400703
 MAHARASHTRA, INDIA
 Tel : 022-39199222,022-49723322,
 FAX : 022-39199222,022-49723322



Scan to View Details



Scan to View Report



Patient Ref. No. 220000081121

PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781**

AGE : 33 Years SEX : Male

ABHA NO :

DRAWN : 26/11/2022 09:00:00

RECEIVED : 26/11/2022 09:02:13

REPORTED : 26/11/2022 12:46:30

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816
CORP-OPD
BILLNO-150122OPCR059785
BILLNO-150122OPCR059785

Test Report Status	Results	Biological Reference Interval
Final		

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).
In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.
Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition;2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin;3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.
RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.
WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.
(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504
This ratio element is a calculated parameter and out of NABL scope.

IMMUNOHAEMATOLOGY

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE B

METHOD : TUBE AGGLUTINATION

RH TYPE

POSITIVE

METHOD : TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-
Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

BIO CHEMISTRY

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL

134

< 200 Desirable
200 - 239 Borderline High
>/= 240 High

mg/dL

METHOD : ENZYMATIC/COLORIMETRIC,CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE


TRIGLYCERIDES

71

< 150 Normal
150 - 199 Borderline High
200 - 499 High
>/=500 Very High

mg/dL

SRL Ltd
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
SECTOR 10,
NAVI MUMBAI, 400703
MAHARASHTRA, INDIA
Tel : 022-39199222,022-49723322,
022-25000000,022-25000000





PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781**

AGE : 33 Years SEX : Male

ABHA NO :

DRAWN : 26/11/2022 09:00:00

RECEIVED : 26/11/2022 09:02:13

REPORTED : 26/11/2022 12:46:30

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816

CORP-OPD

BILLNO-150122OPCR059785

BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval
METHOD : ENZYMATIC ASSAY			
HDL CHOLESTEROL		40	< 40 Low >/=60 High mg/dL
METHOD : DIRECT MEASURE - PEG			
LDL CHOLESTEROL, DIRECT		75	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High mg/dL
METHOD : DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT			
NON HDL CHOLESTEROL		94	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220 mg/dL
METHOD : CALCULATED PARAMETER			
CHOL/HDL RATIO		3.4	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk
METHOD : CALCULATED PARAMETER			
LDL/HDL RATIO		1.9	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk
METHOD : CALCULATED PARAMETER			
VERY LOW DENSITY LIPOPROTEIN		14.2	</= 30.0 mg/dL
METHOD : CALCULATED PARAMETER			


SRL Ltd
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
SECTOR 10,
NAVI MUMBAI, 400703
MAHARASHTRA, INDIA
Tel : 022-39199222,022-49723322,
022-25500000,022-25500000



Scan to View Details



Scan to View Report



PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781**

AGE : 33 Years

SEX : Male

ABHA NO :

DRAWN : 26/11/2022 09:00:00

RECEIVED : 26/11/2022 09:02:13

REPORTED : 26/11/2022 12:46:30



CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816
CORP-OPD
BILLNO-150122OPCR059785
BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------



Scan to View Details



Scan to View Report



PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781**

AGE : 33 Years SEX : Male

ABHA NO :

DRAWN : 26/11/2022 09:00:00

RECEIVED : 26/11/2022 09:02:13

REPORTED : 26/11/2022 12:46:30



CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816
CORP-OPD
BILLNO-150122OPCR059785
BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------



LIVER FUNCTION PROFILE, SERUM

SRL Ltd
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
SECTOR 10,
NAVI MUMBAI, 400703
MAHARASHTRA, INDIA
Tel : 022-39199222,022-49723322,
022-49723322



Scan to View Details



Scan to View Report



PATIENT NAME : MR. MR.SOMDEEP MUKHERJEEPATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781** AGE : 33 Years SEX : Male

ABHA NO :

DRAWN : 26/11/2022 09:00:00

RECEIVED : 26/11/2022 09:02:13

REPORTED : 26/11/2022 12:46:30

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816

CORP-OPD

BILLNO-150122OPCR059785

BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval
BILIRUBIN, TOTAL		0.46	0.2 - 1.0 mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, DIRECT		0.13	0.0 - 0.2 mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, INDIRECT		0.33	0.1 - 1.0 mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN		7.0	6.4 - 8.2 g/dL
METHOD : BIURET			
ALBUMIN		3.3	Low 3.4 - 5.0 g/dL
METHOD : BCP DYE BINDING			
GLOBULIN		3.7	2.0 - 4.1 g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO		0.9	Low 1.0 - 2.1 RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE (AST/SGOT)		16	15 - 37 U/L
METHOD : UV WITH P5P			
ALANINE AMINOTRANSFERASE (ALT/SGPT)		20	< 45.0 U/L
METHOD : UV WITH P5P			
ALKALINE PHOSPHATASE		94	30 - 120 U/L
METHOD : PNPP-ANP			
GAMMA GLUTAMYL TRANSFERASE (GGT)		17	15 - 85 U/L
METHOD : GAMMA GLUTAMYL CARBOXY 4-NITROANILIDE			
LACTATE DEHYDROGENASE		119	100 - 190 U/L
METHOD : LACTATE -PYRUVATE			
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR)		94	74 - 99 mg/dL
METHOD : HEXOKINASE			



Scan to View Details



Scan to View Report



PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781**

AGE : 33 Years

SEX : Male

ABHA NO :

DRAWN : 26/11/2022 09:00:00

RECEIVED : 26/11/2022 09:02:13

REPORTED : 26/11/2022 12:46:30

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :


UID:8178723 REQNO-1325816

CORP-OPD

BILLNO-150122OPCR059785

BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------



GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C 5.2 Non-diabetic: < 5.7 %
 Pre-diabetics: 5.7 - 6.4
 Diabetics: > or = 6.5
 ADA Target: 7.0
 Action suggested: > 8.0

METHOD : HB VARIANT (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) 102.5 < 116.0 mg/dL

METHOD : CALCULATED PARAMETER



Scan to View Details



Scan to View Report



PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781**

AGE : 33 Years

SEX : Male

ABHA NO :

DRAWN : 26/11/2022 09:00:00

RECEIVED : 26/11/2022 09:02:13

REPORTED : 26/11/2022 12:46:30


CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816
CORP-OPD
BILLNO-150122OPCR059785
BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------



Interpretation(s)

LIPID PROFILE, SERUM- Serum cholesterol is a blood test that can provide valuable information for the risk of coronary artery disease. This test can help determine your risk of the build up of plaques in your arteries that can lead to narrowed or blocked arteries throughout your body (atherosclerosis). High cholesterol levels usually don't cause any signs or symptoms, so a cholesterol test is an important tool. High cholesterol levels often are a significant risk factor for heart disease and important for diagnosis of hyperlipoproteinemia, atherosclerosis, hepatic and thyroid diseases.

Serum Triglyceride are a type of fat in the blood. When you eat, your body converts any calories it doesn't need into triglycerides, which are stored in fat cells. High triglyceride levels are associated with several factors, including being overweight, eating too many sweets or drinking too much alcohol, smoking, being sedentary, or having diabetes with elevated blood sugar levels. Analysis has proven useful in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, and various endocrine disorders. In conjunction with high density lipoprotein and total serum cholesterol, a triglyceride determination provides valuable information for the assessment of coronary heart disease risk. It is done in fasting state.

High-density lipoprotein (HDL) cholesterol. This is sometimes called the "good" cholesterol because it helps carry away LDL cholesterol, thus keeping arteries open and blood flowing more freely. HDL cholesterol is inversely related to the risk for cardiovascular disease. It increases following regular exercise, moderate alcohol consumption and with oral estrogen therapy. Decreased levels are associated with obesity, stress, cigarette smoking and diabetes mellitus.

SERUM LDL The small dense LDL test can be used to determine cardiovascular risk in individuals with metabolic syndrome or established/progressing coronary artery disease, individuals with triglyceride levels between 70 and 140 mg/dL, as well as individuals with a diet high in trans-fat or carbohydrates. Elevated sdLDL levels are associated with metabolic syndrome and an 'atherogenic lipoprotein profile', and are a strong, independent predictor of cardiovascular disease. Elevated levels of LDL arise from multiple sources. A major factor is sedentary lifestyle with a diet high in saturated fat. Insulin-resistance and pre-diabetes have also been implicated, as has genetic predisposition. Measurement of sdLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels will reduce the risk of CVD and MI.

Non HDL Cholesterol - Adult treatment panel ATP III suggested the addition of Non-HDL Cholesterol as an indicator of all atherogenic lipoproteins (mainly LDL and VLDL). NICE guidelines recommend Non-HDL Cholesterol measurement before initiating lipid lowering therapy. It has also been shown to be a better marker of risk in both primary and secondary prevention studies.

Recommendations:

Results of Lipids should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

SRL Ltd
HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
SECTOR 10,
NAVI MUMBAI, 400703
MAHARASHTRA, INDIA
Tel : 022-39199222, 022-49723322,
022-49723322



Scan to View Details



Scan to View Report



PATIENT NAME : MR. MR.SOMDEEP MUKHERJEEPATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781** AGE : 33 Years SEX : Male ABHA NO :
 DRAWN : 26/11/2022 09:00:00 RECEIVED : 26/11/2022 09:02:13 REPORTED : 26/11/2022 12:46:30

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816
 CORP-OPD
 BILLNO-1501220PCR059785
 BILLNO-1501220PCR059785

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------

NON FASTING LIPID PROFILE includes Total Cholesterol, HDL Cholesterol and calculated non-HDL Cholesterol. It does not include triglycerides and may be best used in patients for whom fasting is difficult.

LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels result from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease. Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g., galactosemia), Drugs- insulin, ethanol, propranolol; sulfonyleureas, tolbutamide, and other oral hypoglycemic agents.

NOTE:

Hypoglycemia is defined as a glucose of < 50 mg/dL in men and < 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN (HbA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

HbA1c Estimation can get affected due to:

- I. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g, recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin).
- III. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
- IV. Interference of hemoglobinopathies in HbA1c estimation is seen in
 - a. Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
 - b. Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
 SECTOR 10,
 NAVI MUMBAI, 400703
 MAHARASHTRA, INDIA
 Tel : 022-39199222, 022-49723322,
 FAX : 022-39199222, 022-49723322



Scan to View Details



Scan to View Report

Page 15 Of 16



Patient Ref. No. 2200000811214

PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781**

AGE : 33 Years

SEX : Male

ABHA NO :

DRAWN : 26/11/2022 09:00:00

RECEIVED : 26/11/2022 09:02:13

REPORTED : 26/11/2022 12:46:30

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816

CORP-OPD

BILLNO-150122OPCR059785

BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------

c.HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy


****End Of Report****

Please visit www.srlworld.com for related Test Information for this accession



Dr. Akta Dubey

Consultant Pathologist



Dr. Rekha Nair, MD

Microbiologist

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
SECTOR 10,
NAVI MUMBAI, 400703
MAHARASHTRA, INDIA
Tel : 022-39199222, 022-49723322,
022-49723322



Scan to View Details



Scan to View Report



PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723** CLIENT PATIENT ID : UID:8178723
 ACCESSION NO : **0022VK005781** AGE : 33 Years SEX : Male ABHA NO :
 DRAWN : 26/11/2022 09:00:00 RECEIVED : 26/11/2022 09:02:13 REPORTED : 26/11/2022 16:30:14
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816
 CORP-OPD
 BILLNO-150122OPCR059785
 BILLNO-150122OPCR059785

Test Report Status	Results	Biological Reference Interval	Units
Final			

SPECIALISED CHEMISTRY - HORMONE

THYROID PANEL, SERUM

T3	127.3	80 - 200	ng/dL
METHOD : ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY			
T4	7.86	5.1 - 14.1	µg/dL
METHOD : ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY			
TSH (ULTRASENSITIVE)	2.450	0.270 - 4.200	µIU/mL
METHOD : ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY			

Interpretation(s)



Scan to View Details



Scan to View Report



PATIENT NAME : MR. MR.SOMDEEP MUKHERJEEPATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781**

AGE : 33 Years

SEX : Male

ABHA NO :

DRAWN : 26/11/2022 09:00:00

RECEIVED : 26/11/2022 09:02:13

REPORTED : 26/11/2022 16:30:14

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816

CORP-OPD

BILLNO-150122OPCR059785

BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

SPECIALISED CHEMISTRY - TUMOR MARKER**PROSTATE SPECIFIC ANTIGEN, SERUM**

PROSTATE SPECIFIC ANTIGEN

0.609

< 1.4

ng/mL

METHOD : ELECTROCHEMILUMINESCENCE,SANDWICH IMMUNOASSAY

Interpretation(s)

PROSTATE SPECIFIC ANTIGEN, SERUM-- PSA is detected in the male patients with normal, benign hyperplastic and malignant prostate tissue and in patients with prostatitis. - PSA is not detected (or detected at very low levels) in the patients without prostate tissue (because of radical prostatectomy or cystoprostatectomy) and also in the female patient.

- It a suitable marker for monitoring of patients with Prostate Cancer and it is better to be used in conjunction with other diagnostic procedures.

- Serial PSA levels can help determine the success of prostatectomy and the need for further treatment, such as radiation, endocrine or chemotherapy and useful in detecting residual disease and early recurrence of tumor.

- Elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benign Prostatic Hyperplasia.

- Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA (false positive) levels persisting up to 3 weeks.

- As per American urological guidelines, PSA screening is recommended for early detection of Prostate cancer above the age of 40 years. Following Age specific reference range can be used as a guide lines-

Age of male	Reference range (ng/ml)
40-49 years	0-2.5
50-59 years	0-3.5
60-69 years	0-4.5
70-79 years	0-6.5

(* conventional reference level (< 4 ng/ml) is already mentioned in report, which covers all agegroup with 95% prediction interval)

References- Teitz ,textbook of clinical chemistry, 4th edition) 2.Wallach's Interpretation of Diagnostic Tests

****End Of Report******Please visit www.srlworld.com for related Test Information for this accession**


786

Dr. Swapnil Sirmukaddam**Consultant Pathologist****SRL Ltd**

BHOO MI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR

4, KHARGHAR

NAVI MUMBAI, 410210

MAHARASHTRA, INDIA

Tel : 9111591115,

Fax : 9111591115



Scan to View Details



Scan to View Report

Page 2 Of 2

**Patient Ref. No. 2200000811214**

PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723** CLIENT PATIENT ID : UID:8178723
 ACCESSION NO : **0022VK005858** AGE : 33 Years SEX : Male ABHA NO :
 DRAWN : 26/11/2022 11:43:00 RECEIVED : 26/11/2022 11:43:36 REPORTED : 26/11/2022 13:12:35
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR :

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816
 CORP-OPD
 BILLNO-150122OPCR059785
 BILLNO-150122OPCR059785


Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIO CHEMISTRY

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 96 70 - 139 mg/dL

METHOD : HEXOKINASE



Interpretation(s)

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c

****End Of Report****

Please visit www.srlworld.com for related Test Information for this accession



Scan to View Details



Scan to View Report



11/26/2022 11:26:02 AM

Mr somdeep mukherjee
Male

8178723
33 Years

Rate 65 . Sinus rhythm.....normal P axis, V-rate 50- 99
PR 174 . ST elev, probable normal early repol pattern.....ST elevation, age<55

QRSD 87
QT 385
QTc 401


--AXIS--

P 41
QRS -1
T 12

12 Lead; Standard Placement

- NORMAL ECG -

Unconfirmed Diagnosis



F 50~ 0.50-100 HZ W 100B CL P?

Speed: 25 mm/sec Limb: 10 mm/mV Chest: 10.0 mm/mV

Device:



DEPARTMENT OF NIC

Date: 26/Nov/2022

Name: Mr. Somdeep Mukherjee
Age | Sex: 33 YEAR(S) | Male
Order Station : FO-OPD
Bed Name :

UHID | Episode No : 8178723 | 59227/22/1501
Order No | Order Date: 1501/PN/OP/2211/125813 | 26-Nov-2022
Admitted On | Reporting Date : 26-Nov-2022 14:07:23
Order Doctor Name : Dr.SELF .

ECHOCARDIOGRAPHY TRANSTHORACIC

FINDINGS:

- No left ventricle regional wall motion abnormality at rest.
- Normal left ventricle systolic function. LVEF = 60%.
- No left ventricle diastolic dysfunction.
- No left ventricle Hypertrophy. No left ventricle dilatation.
- Structurally normal valves.
- No mitral regurgitation.
- No aortic regurgitation. No aortic stenosis.
- No tricuspid regurgitation. No pulmonary hypertension.
- Intact IAS and IVS.
- No left ventricle clot/vegetation/pericardial effusion.
- Normal right atrium and right ventricle dimensions.
- Normal left atrium and left ventricle dimension.
- Normal right ventricle systolic function. No hepatic congestion

M-MODE MEASUREMENTS:

LA	32	mm
AO Root	25	mm
AO CUSP SEP	16	mm
LVID (s)	26	mm
LVID (d)	39	mm
IVS (d)	08	mm
LVPW (d)	08	mm
RVID (d)	27	mm
RA	20	mm
LVEF	60	%



DEPARTMENT OF NIC

Date: 26/Nov/2022

Name: Mr. Somdeep Mukherjee
Age | Sex: 33 YEAR(S) | Male
Order Station : FO-OPD
Bed Name :

UHID | Episode No : 8178723 | 59227/22/1501
Order No | Order Date: 1501/PN/OP/2211/125813 | 26-Nov-2022
Admitted On | Reporting Date : 26-Nov-2022 14:07:23
Order Doctor Name : Dr.SELF .

DOPPLER STUDY:

E WAVE VELOCITY: 0.9 m/sec.
A WAVE VELOCITY: 0.6 m/sec
E/A RATIO: 1.5

	PEAK (mmHg)	MEAN (mmHg)	V max (m/sec)	GRADE OF REGURGITATION
MITRAL VALVE	N			Nil
AORTIC VALVE	05			Nil
TRICUSPID VALVE	12			Nil
PULMONARY VALVE	04			Nil

Final Impression :

Normal 2 Dimensional and colour doppler echocardiography study.


DR. PRASHANT PAWAR
DNB (MED), DNB (CARDIOLOGY)



DEPARTMENT OF RADIOLOGY

Date: 26/Nov/2022

Name: Mr. Somdeep Mukherjee

Age | Sex: 33 YEAR(S) | Male

Order Station : FO-OPD

Bed Name :

UHID | Episode No : 8178723 | 59227/22/1501

Order No | Order Date: 1501/PN/OP/2211/125813 | 26-Nov-2022

Admitted On | Reporting Date : 26-Nov-2022 11:04:04

Order Doctor Name : Dr.SELF.

X-RAY-CHEST- PA

Findings:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Incidentally noted partial left 1st rib.

DR. CHETAN KHADKE

M.D. (Radiologist)



DEPARTMENT OF RADIOLOGY

Date: 26/Nov/2022

Name: Mr. Somdeep Mukherjee
Age | Sex: 33 YEAR(S) | Male
Order Station : FO-OPD
Bed Name :

UHID | Episode No : 8178723 | 59227/22/1501
Order No | Order Date: 1501/PN/OP/2211/125813 | 26-Nov-2022
Admitted On | Reporting Date : 26-Nov-2022 10:12:39
Order Doctor Name : Dr.SELF .

US-WHOLE ABDOMEN

LIVER is normal in size (13.8 cm) and shows raised echogenicity. Intrahepatic portal and biliary systems are normal. No focal lesion is seen in liver. Portal vein appears normal (8.4 mm).

GALL BLADDER is minimally distended. A tiny echogenic focus of size 3 mm is noted within the lumen – possibility of calculus.

SPLEEN is normal in size (10.9 cm) and echogenicity.

BOTH KIDNEYS are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.
Right kidney measures 9.4 x 5.2 cm. *A tiny concretion of size 2 mm noted in mid pole of right kidney.*
Left kidney measures 8.7 x 5.3 cm.

PANCREAS: Head and body of pancreas appear unremarkable. Rest of the pancreas is obscured.

URINARY BLADDER is normal in capacity and contour. Bladder wall is normal in thickness. No evidence of intravesical mass/calculi.

PROSTATE is normal in size & echogenicity. It measures ~ 12.4 cc in volume.

No evidence of ascites.

IMPRESSION:

- *Fatty infiltration of liver.*
- *Tiny echogenic focus within the lumen – possibility of calculus. Suggest: Review in fasting stage and fat free diet for better evaluation of gall bladder / CT abdomen if clinically indicated.*


DR. YOGESH PATHADE
(MD Radio-diagnosis)



UHID	8178723	Date	26/11/2022		
Name	Mr.Somdeep Mukherjee	Sex	Male	Age	33
OPD	Opthal 14	Health Check Up			

Drug allergy:
 Sys illness:

AB opthal.

Vn 5 6/6
 6/6

6/6: Asymet

Indus
 Ann TWK

Rx.

Eye drops REGULAR.
 1-1-1
 (OT) x/mth

Zero power

(use blue block
 are glasses)

Handwritten signature



UHID	8178723	Date	26/11/2022		
Name	Mr.Somdeep Mukherjee	Sex	Male	Age	33
OPD	Dental 12	Health Check Up			

Impacted 8/

Cavious 76/7

Drug allergy:
Sys illness:

Stains 8/
calculus 7

Treatment

Adv. surgical removal 8/

Adv. filling 76/7

Adv. oral prophylaxis.

Dr. Diksha Kedar

PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723** CLIENT PATIENT ID : UID:8178723
 ACCESSION NO : **0022VK005781** AGE : 33 Years SEX : Male ABHA NO :
 DRAWN : 26/11/2022 09:00:00 RECEIVED : 26/11/2022 09:02:13 REPORTED : 26/11/2022 12:46:30
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF


CLINICAL INFORMATION :
 UID:8178723 REQNO-1325816
 CORP-OPD
 BILLNO-150122OPCR059785
 BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

KIDNEY PANEL - 1

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN 8 6 - 20 mg/dL
 METHOD : UREASE - UV



CREATININE EGFR- EPI

CREATININE **0.88** Low 0.90 - 1.30 mg/dL
 METHOD : ALKALINE PICRATE KINETIC JAFFES
 AGE 33 years
 GLOMERULAR FILTRATION RATE (MALE) 116.44 Refer Interpretation Below mL/min/1.73m2
 METHOD : CALCULATED PARAMETER



Scan to View Details



Scan to View Report



Patient Ref. No. 2200000811214

**PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE**PATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781**

AGE : 33 Years

SEX : Male

ABHA NO :

DRAWN : 26/11/2022 09:00:00

RECEIVED : 26/11/2022 09:02:13

REPORTED : 26/11/2022 12:46:30

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816

CORP-OPD

BILLNO-150122OPCR059785

BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

METHOD : ISE INDIRECT

CHLORIDE, SERUM

102

98 - 107

mmol/L

METHOD : ISE INDIRECT

Interpretation(s)**PHYSICAL EXAMINATION, URINE**

COLOR

PALE YELLOW

METHOD : PHYSICAL

APPEARANCE

CLEAR

METHOD : VISUAL

CHEMICAL EXAMINATION, URINE

PH

6.5

4.7 - 7.5

METHOD : REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD

SPECIFIC GRAVITY

<=1.005

1.003 - 1.035

METHOD : REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)

PROTEIN

NOT DETECTED

NOT DETECTED

METHOD : REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE

GLUCOSE

NOT DETECTED

NOT DETECTED

METHOD : REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD

KETONES

NOT DETECTED

NOT DETECTED

METHOD : REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE

BLOOD

NOT DETECTED

NOT DETECTED

METHOD : REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN

BILIRUBIN

NOT DETECTED

NOT DETECTED

METHOD : REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT

UROBILINOGEN

NORMAL

NORMAL

METHOD : REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRlich REACTION)

NITRITE

NOT DETECTED

NOT DETECTED

METHOD : REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE

LEUKOCYTE ESTERASE

NOT DETECTED

NOT DETECTED

METHOD : REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF

METHOD : MICROSCOPIC EXAMINATION

PUS CELL (WBC'S)

0-1

0-5

/HPF

METHOD : MICROSCOPIC EXAMINATION

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,

SECTOR 10,

NAVI MUMBAI, 400703

MAHARASHTRA, INDIA

Tel : 022-39199222,022-49723322,

022-49723322,022-49723322



Scan to View Details



Scan to View Report



**PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE**PATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781**

AGE : 33 Years

SEX : Male

ABHA NO :

DRAWN : 26/11/2022 09:00:00

RECEIVED : 26/11/2022 09:02:13

REPORTED : 26/11/2022 12:46:30

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816

CORP-OPD

BILLNO-150122OPCR059785

BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval	Units
EPITHELIAL CELLS		1-2	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION				
CASTS		NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
CRYSTALS		NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
BACTERIA		NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION				
YEAST		NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION				
REMARKS		URINARY MICROSCOPIC EXAMINATION DONE ON URINARY CENTRIFUGED SEDIMENT URINARY		

Interpretation(s)**Interpretation(s)**

BLOOD UREA NITROGEN (BUN), SERUM- Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)
Causes of decreased level include Liver disease, SIADH.

CREATININE EGFR- EPI-

GFR— Glomerular filtration rate (GFR) is a measure of the function of the kidneys. The GFR is a calculation based on a serum creatinine test. Creatinine is a muscle waste product that is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, less creatinine is excreted and concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined.

A GFR of 60 or higher is in the normal range.

A GFR below 60 may mean kidney disease.

A GFR of 15 or lower may mean kidney failure.

Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Renal Disease (MDRD) Study equation provides a more clinically useful measure of kidney function than serum creatinine alone.

The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimated GFR and serum creatinine, and a different relationship for age, sex and race. The equation was reported to perform better and with less bias than the MDRD Study equation especially in patients with higher GFR. This results in reduced misclassification of CKD.

The CKD-EPI creatinine equation has not been validated in children & will only be reported for patients = 18 years of age. For pediatric and childrens, Schwartz Pediatric Bedside eGFR (2009) formulae is used. This revised "bedside" pediatric eGFR requires only serum creatinine and height.

URIC ACID, SERUM-

Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome

Causes of decreased levels:-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-

Serum total protein,also known as total protein, is a biochemical test for measuring the total amount of protein in serum..Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution,

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,

SECTOR 10,

NAVI MUMBAI, 400703

MAHARASHTRA, INDIA

Tel : 022-39199222,022-49723322,

022-49723322



Scan to View Details



Scan to View Report





PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723**

CLIENT PATIENT ID : UID:8178723

ACCESSION NO : **0022VK005781**

AGE : 33 Years SEX : Male

ABHA NO :

DRAWN : 26/11/2022 09:00:00

RECEIVED : 26/11/2022 09:02:13

REPORTED : 26/11/2022 12:46:30

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816

CORP-OPD

BILLNO-150122OPCR059785

BILLNO-150122OPCR059785

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------

increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.



Scan to View Details



Scan to View Report



PATIENT NAME : MR. MR.SOMDEEP MUKHERJEE

PATIENT ID : **FH.8178723** CLIENT PATIENT ID : UID:8178723
 ACCESSION NO : **0022VK005781** AGE : 33 Years SEX : Male ABHA NO :
 DRAWN : 26/11/2022 09:00:00 RECEIVED : 26/11/2022 09:02:13 REPORTED : 26/11/2022 12:46:30
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

CLINICAL INFORMATION :

UID:8178723 REQNO-1325816
 CORP-OPD
 BILLNO-1501220PCR059785
 BILLNO-1501220PCR059785

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------

HAEMATOLOGY

CBC-5, EDTA WHOLE BLOOD

MORPHOLOGY

RBC PREDOMINANTLY NORMOCYTIC NORMOCHROMIC
 METHOD : MICROSCOPIC EXAMINATION
 WBC MILD LEUCOPENIA
 METHOD : MICROSCOPIC EXAMINATION
 PLATELETS ADEQUATE
 METHOD : MICROSCOPIC EXAMINATION

ERYTHROCYTE SEDIMENTATION RATE (ESR).WHOLE BLOOD

E.S.R **21** High 0 - 14 mm at 1 hr
 METHOD : WESTERGREN METHOD

CBC-5, EDTA WHOLE BLOOD

BLOOD COUNTS, EDTA WHOLE BLOOD

HEMOGLOBIN (HB)	13.2	13.0 - 17.0	g/dL
METHOD : SPECTROPHOTOMETRY			
RED BLOOD CELL (RBC) COUNT	4.08	Low 4.5 - 5.5	mil/ μ L
METHOD : ELECTRICAL IMPEDANCE			
WHITE BLOOD CELL (WBC) COUNT	3.73	Low 4.0 - 10.0	thou/ μ L
METHOD : DOUBLE HYDRODYNAMIC SEQUENTIAL SYSTEM(DHSS)CYTOMETRY			
PLATELET COUNT	216	150 - 410	thou/ μ L
METHOD : ELECTRICAL IMPEDANCE			
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	39.6	Low 40 - 50	%
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR VOLUME (MCV)	97.2	83 - 101	fL
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	32.4	High 27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC)	33.3	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			



Scan to View Details



Scan to View Report